Haemonetics - תחזית צמיחת רווח נקי למניה לשנה הבאה HAE

Haemonetics Corporation (HAE) hematology system production capacities are operating at full throttle as they undergo an automation phase. The EPS growth rate target for next year on GURU.Markets reflects the trend of expectations, where the 16.40 metric determines this level. The development of NexSys PCS and hospital software is driving revenues, while the implementation of ESG standards in production is reducing the environmental footprint.

Haemonetics Corporation (HAE) is laying the foundation for future revenue scaling through an active M&A strategy in the vascular startup sector and the automation of plasma collection. This growth trajectory is reflected in the calculations of expected net income per share growth, which aggregates expert forecasts for future earnings, allowing the issuer's market potential to be assessed via the trend of consensus EPS estimates.